Methylprednisolone acetateCAS# 53-36-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 53-36-1 | SDF | Download SDF |
| PubChem ID | 5877 | Appearance | Powder |
| Formula | C24H32O6 | M.Wt | 416.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate | ||
| SMILES | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O | ||
| Standard InChIKey | PLBHSZGDDKCEHR-LFYFAGGJSA-N | ||
| Standard InChI | InChI=1S/C24H32O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h5,7,10,13,16-17,19,21,27,29H,6,8-9,11-12H2,1-4H3/t13-,16-,17-,19-,21+,22-,23-,24-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Methylprednisolone acetate Dilution Calculator
Methylprednisolone acetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.401 mL | 12.0048 mL | 24.0096 mL | 48.0192 mL | 60.024 mL |
| 5 mM | 0.4802 mL | 2.401 mL | 4.8019 mL | 9.6038 mL | 12.0048 mL |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.401 mL | 4.8019 mL | 6.0024 mL |
| 50 mM | 0.048 mL | 0.2401 mL | 0.4802 mL | 0.9604 mL | 1.2005 mL |
| 100 mM | 0.024 mL | 0.12 mL | 0.2401 mL | 0.4802 mL | 0.6002 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cocaine hydrochloride
Catalog No.:BCC5943
CAS No.:53-21-4
- Mitotane (Lsodren)
Catalog No.:BCC3815
CAS No.:53-19-0
- Estrone
Catalog No.:BCN2201
CAS No.:53-16-7
- Prednisone
Catalog No.:BCC4957
CAS No.:53-03-2
- Acetylisocupressic acid
Catalog No.:BCN5695
CAS No.:52992-82-2
- Ajugol
Catalog No.:BCN2883
CAS No.:52949-83-4
- Genz-644282
Catalog No.:BCC1592
CAS No.:529488-28-6
- N-(2,6-Diphenylmethyl)-1-piperazine acetylamine
Catalog No.:BCC9052
CAS No.:5294-61-1
- Nanaomycin A
Catalog No.:BCC3611
CAS No.:52934-83-5
- Neosophoramine
Catalog No.:BCN5690
CAS No.:52932-74-8
- Dammaradienyl acetate
Catalog No.:BCN5689
CAS No.:52914-31-5
- PRIMA-1MET
Catalog No.:BCC2414
CAS No.:5291-32-7
- Oxandrolone
Catalog No.:BCC5242
CAS No.:53-39-4
- Dehydroepiandrosterone
Catalog No.:BCN2202
CAS No.:53-43-0
- Indomethacin
Catalog No.:BCC3794
CAS No.:53-86-1
- L-Picein
Catalog No.:BCC8336
CAS No.:530-14-3
- Deoxyvasicinone
Catalog No.:BCN5697
CAS No.:530-53-0
- 2,6-Dimethoxy-1,4-benzoquinone
Catalog No.:BCN5698
CAS No.:530-55-2
- Syringic acid
Catalog No.:BCN5699
CAS No.:530-57-4
- Sinapic acid
Catalog No.:BCN3539
CAS No.:530-59-6
- CDI (1,1′-Carbonyldiimidazole)
Catalog No.:BCC2809
CAS No.:530-62-1
- Salinomycin
Catalog No.:BCC1916
CAS No.:53003-10-4
- Murralongin
Catalog No.:BCN5696
CAS No.:53011-72-6
- T-5224
Catalog No.:BCC5383
CAS No.:530141-72-1
A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department.[Pubmed:30449536]
Ann Emerg Med. 2019 Feb;73(2):141-149.
STUDY OBJECTIVE: Migraine patients continue to report headache during the days and weeks after emergency department (ED) discharge. Dexamethasone is an evidence-based treatment of acute migraine that decreases the frequency of moderate or severe headache within 72 hours of ED discharge. We hypothesize that intramuscular Methylprednisolone acetate, a long-acting steroid that remains biologically active for 14 days, will decrease the number of days with headache during the week after ED discharge by at least 1 day compared with intramuscular dexamethasone. METHODS: We conducted a randomized, blinded clinical trial comparing intravenous metoclopramide at 10 mg+intramuscular dexamethasone at 10 mg with intravenous metoclopramide at 10 mg+intramuscular Methylprednisolone acetate at a dose of 160 mg for patients presenting to 2 different EDs with moderate or severe migraine. Outcomes were assessed by telephone with a standardized instrument. The primary outcome was number of days with headache during the week after ED discharge. Secondary outcomes were complete freedom from headache, without the necessity of additional headache medication for the entire week after ED discharge, and medication preference, as determined by asking the patient whether he or she would want to receive the same medication again. RESULTS: One hundred nine patients received dexamethasone and 111 received Methylprednisolone acetate. We obtained primary outcome data from 101 dexamethasone patients and 106 Methylprednisolone acetate patients. Dexamethasone patients reported 3.0 headache days and Methylprednisolone acetate 3.3 headache days (95% confidence interval for rounded mean difference of 0.4 days: -0.4 to 1.1). Of 107 dexamethasone patients with analyzable data, 10 (9%) reported complete freedom from headache at 1 week versus 6 of 110 (5%) Methylprednisolone acetate patients (95% confidence interval for difference of 4%: -3% to 11%). In the dexamethasone group, 76 of 101 (75%) patients would want the same medication again versus 75 of 106 (71%) of Methylprednisolone acetate patients (95% confidence interval for difference of 4%: -8% to 17%). Other than injection site reactions, which were more common in the Methylprednisolone acetate group, there were no substantial differences in frequency of adverse events. CONCLUSION: Methylprednisolone acetate does not decrease the frequency of post-ED discharge headache days compared with dexamethasone. Most migraine patients are likely to continue to experience headache during the week after ED discharge.
